First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (2217LS) Against Borrelia Burgdorferi (B. Burgdorferi) Outer Surface Protein A (OspA)

This is a research study of the investigational drug 2217LS in healthy volunteers. Investigational means 2217LS is a new drug that has not been approved for the treatment of any disease. 2217LS is human antibody designed to provide protection from Lyme disease. Lyme disease is a disease carried by infected ticks and can cause the infection to spread to the joints, heart and nervous system in humans.

This is the first time 2217LS will be given to humans. This is not a study of how well 2217LS works against Lyme disease. The only purposes of this study are to: 1) Learn about the safety and tolerability of a subcutaneous (SC [under the skin]) injection of 2217LS when administered to healthy volunteers. 2) Find out how much 2217LS is in the blood of healthy volunteers after receiving 2217LS SC.

In this study, groups of healthy volunteers will be given different doses of 2217LS by SC injection. Volunteers will stay in the study unit for a total of 4 overnights. The planned duration of participation is up to 14 months. Study personnel will monitor their safety using standard procedures like physical examinations, electrocardiograms, questions about possible side effects, blood and urine tests. The amount of 2217LS in their blood will also be measured.

Study Overview

• Status: Completed
• Conditions: Lyme Disease
• Intervention / Treatment: Biological: 2217LS; Other: 0.9% Sodium Chloride (NaCl)

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Nebraska
    • Lincoln, Nebraska, United States, 68502
      • Celerion Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Capable of giving written informed consent and able to effectively communicate with the Investigator and study personnel. A signed informed consent form (ICF) must be on file prior to initiating the screening procedures.
2. Willing and able to complete all study requirements, restrictions, visits and procedures.
3. Negative for serum anti-B. burgdorferi antibodies by an FDA approved modified two-tier ELISA test.
4. Age 19 to 65 years, inclusive.
5. Weight 50 kg to 105 kg, inclusive.
6. Seated blood pressure is greater than 90/40 mmHg or less than 140/90 mmHg at the screening visit, and seated heart rate is higher than 40 bpm or lower than 99 bpm at the screening visit.
7. Women of reproductive potential must agree not to become pregnant for at least 12 months after the study product administration. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel.
8. Males of reproductive potential must use a barrier method of contraception during the course of the study.

9. Screening laboratory values must meet the following criteria:

   • WBC > 3,900 and < 11,000/mm3
   • Platelets > 100,000/mm3
   • Hemoglobin > 10.5 gm/dl
   • Creatinine ≤ ULN
   • BUN ≤ ULN
   • AST ≤ ULN
   • ALT ≤ ULN
   • Alkaline Phosphatase ≤ ULN
   • Total Bilirubin < 1.5 x ULN AND Direct Bilirubin ≤ ULN
   • HgbA1c ≤ 6.4

Exclusion Criteria:

1. Previous receipt of humanized or human monoclonal antibody whether licensed or investigational.
2. Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen.
3. Regular use of more than 20 cigarettes per day (or equivalent amount of nicotine containing product)
4. Drug or alcohol abuse within previous 12 months or a positive screen within 24 hours of study product administration.
5. History of a previous severe allergic reaction with generalized urticaria, angioedema or anaphylaxis.
6. Any current medical or other condition that in the opinion of the PI would jeopardize the safety of the volunteer participating in the study.
7. Clinically significant gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease, as determined by the PI. The investigator will consider all conditions, which could conceivably increase risk to the subjects, alter study drug metabolism, or jeopardize data integrity as clinically significant when making this determination.
8. Physical finding on examination considered clinically significant such as murmur (other than functional), hepatosplenomegaly, lymphadenopathy or focal neurological deficit.
9. Positive serum pregnancy test during screening or within 24 hours of study product administration, or an unwillingness to undergo pregnancy testing.
10. Breast-feeding.
11. Treatment with another investigational drug or other investigational intervention within 30 days of study drug dosing.
12. Safety laboratory abnormalities at Screening or Day -1, which are clinically significant as determined by the PI.
13. Tick bite within 4 weeks prior to screening.
14. Receipt of any Lyme disease vaccine.

Abnormal ECG or laboratory parameters may be repeated once, if in the opinion of the PI, the results are due to technical factors or are inconsistent with the potential subject's medical evaluation.

Potential study subjects who met all inclusion and none of the exclusion criteria, but who, for personal or administrative reasons, were not included in a study cohort, may be rescreened if more than 30 days have passed since their previous screening. There are no restrictions on the number of re-screens permitted for these subjects.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 0.5 mg/kg of 2217LS; Single dose subcutaneous injection	Biological: 2217LS; Fully Human Monoclonal Antibody
Experimental: 1.5 mg/kg of 2217LS; Single dose subcutaneous injection	Biological: 2217LS; Fully Human Monoclonal Antibody
Experimental: 5 mg/kg of 2217LS; Single dose subcutaneous injection	Biological: 2217LS; Fully Human Monoclonal Antibody
Experimental: 10 mg/kg of 2217LS; Single dose subcutaneous injection	Biological: 2217LS; Fully Human Monoclonal Antibody
Placebo Comparator: 0.9% Sodium Chloride (NaCl); Single dose subcutaneous injection	Other: 0.9% Sodium Chloride (NaCl); Subcutaneous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of a study treatment by number of adverse events reported	Adverse events will be assessed by targeted medical history, physical examination, and laboratory testing. Abnormal laboratory values constitute adverse events only if they induce signs or symptoms and/or require therapy that are new or enhanced from baseline. Injection site reactions (pain, tenderness, erythema/redness, and induration/swelling) will be evaluated pre-dose through Day 15. The reactions are rated Mild (Grade 1), Moderate (Grade 2), and Severe (Grade 3) according to FDA guidance for industry. Adverse events will be summarized by System Organ Class (SOC) using MedDRA.	Day 1 through Day 360

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK) parameter: Maximum serum concentration observed (Cmax) of 2217LS	Serial measurements of 2217LS concentration in the serum.	14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360
Pharmacokinetics (PK) parameter: Area under the curve (AUC) of 2217LS	Serial measurements of 2217LS concentration in the serum.	14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360
Pharmacokinetics (PK) parameter: Serum half life (T 1/2) of 2217LS	Serial measurements of 2217LS concentration in the serum.	14 Study Days - Day-1 Pre Dose, Day 2 or 3, 4 or 5, 6 or 7, 8 or 9, 10 or 11, 14 or 15, 29, 60, 90, 120, 180, 240, 360
Assessment of immunogenicity anti-drug antibodies (ADA) of 2217LS	Serial measurements of 2217LS concentration in the serum.	10 Study Days - Day 1 Pre-Dose, Day 8 or 9, 14 or 15, 29, 60, 90, 120, 180, 240, 360

Collaborators and Investigators

• Sponsor: MassBiologics
• Collaborators: Celerion

Study record dates

Study Major Dates

• Study Start (Actual): February 11, 2021
• Primary Completion (Actual): August 16, 2022
• Study Completion (Actual): August 16, 2022

Study Registration Dates

• First Submitted: April 14, 2021
• First Submitted That Met QC Criteria: April 23, 2021
• First Posted (Actual): April 28, 2021

Study Record Updates

• Last Update Posted (Actual): September 16, 2022
• Last Update Submitted That Met QC Criteria: September 15, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Human Monoclonal Antibody; LYME; Lyme bacteria; Borrelia burgdorferi (B. burgdorferi); Outer surface protein A (OspA)
• Additional Relevant MeSH Terms: Infections; Vector Borne Diseases; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Tick-Borne Diseases; Borrelia Infections; Spirochaetales Infections; Lyme Disease
• Other Study ID Numbers: MBL-LYME-20-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No